Patents by Inventor Steven K. Grinspoon
Steven K. Grinspoon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240091316Abstract: The present application relates to novel methods for preventing, slowing the progression of, or treating nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), and/or liver fibrosis, and/or reducing the risks of liver cancer in subjects, such as HIV-infected subjects, using a GHRH molecule, e.g., trans-3-hexenoyl-GHRH(1-44)-NH2, or a pharmaceutically acceptable salt thereof. The subjects may have particular pathological features such as liver fibrosis, a hepatic fat fraction (HFF) of at least about 10%, serum alanine aminotransferase (ALT) levels of at least about 30 U/L, and/or a NAFLD Activity Score (NAS) of at least 4 or 5.Type: ApplicationFiled: July 12, 2023Publication date: March 21, 2024Applicant: The General Hospital CorporationInventor: Steven K. GRINSPOON
-
Publication number: 20230393148Abstract: The present application relates to methods, reagents and kits for the assessment of the severity of nonalcoholic fatty liver disease (NAFLD) in a patient over time, and/or of the likelihood that a subject suffers from NAFLD. The methods, reagents and kits are based on the determination of the levels of VEGFA, TGFB1, and/or CSF1 in a biological sample, such as a plasma sample, from the subject. The methods, reagents and kits may be used, for example, for assessing the progression of NAFLD in a patient and/or the response of the patient to therapy.Type: ApplicationFiled: October 26, 2021Publication date: December 7, 2023Applicant: The General Hospital CorporationInventor: Steven K. Grinspoon
-
Patent number: 11738066Abstract: The present application relates to novel methods for preventing, slowing the progression of, or treating nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), and/or liver fibrosis, and/or reducing the risks of liver cancer in subjects, such as HIV-infected subjects, using a GHRH molecule, e.g., trans-3-hexenoyl-GHRH(1-44)-NH2, or a pharmaceutically acceptable salt thereof. The subjects may have particular pathological features such as liver fibrosis, a hepatic fat fraction (HFF) of at least about 10%, serum alanine aminotransferase (ALT) levels of at least about 30 U/L, and/or a NAFLD Activity Score (NAS) of at least 4 or 5.Type: GrantFiled: February 8, 2021Date of Patent: August 29, 2023Assignee: The General Hospital CorporationInventor: Steven K. Grinspoon
-
Publication number: 20210177943Abstract: The present application relates to novel methods for preventing, slowing the progression of, or treating nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), and/or liver fibrosis, and/or reducing the risks of liver cancer in subjects, such as HIV-infected subjects, using a GHRH molecule, e.g., trans-3-hexenoyl-GHRH(1-44)-NH2, or a pharmaceutically acceptable salt thereof. The subjects may have particular pathological features such as liver fibrosis, a hepatic fat fraction (HFF) of at least about 10%, serum alanine aminotransferase (ALT) levels of at least about 30 U/L, and/or a NAFLD Activity Score (NAS) of at least 4 or 5.Type: ApplicationFiled: February 8, 2021Publication date: June 17, 2021Applicant: The General Hospital CorporationInventor: Steven K. GRINSPOON
-
Patent number: 10946073Abstract: The present application relates to novel methods for preventing, slowing the progression of, or treating nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), and/or liver fibrosis, and/or reducing the risks of liver cancer in subjects, such as HIV-infected subjects, using a GHRH molecule, e.g., trans-3-hexenoyl-GHRH(1-44)-NH2, or a pharmaceutically acceptable salt thereof. The subjects may have particular pathological features such as liver fibrosis, a hepatic fat fraction (HFF) of at least about 10%, serum alanine aminotransferase (ALT) levels of at least about 30 U/L, and/or a NAFLD Activity Score (NAS) of at least 4 or 5.Type: GrantFiled: September 11, 2020Date of Patent: March 16, 2021Assignee: THE GENERAL HOSPITAL CORPORATIONInventor: Steven K. Grinspoon
-
Publication number: 20200405816Abstract: The present application relates to novel methods for preventing, slowing the progression of, or treating nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), and/or liver fibrosis, and/or reducing the risks of liver cancer in subjects, such as HIV-infected subjects, using a GHRH molecule, e.g., trans-3-hexenoyl-GHRH(1-44)-NH2, or a pharmaceutically acceptable salt thereof. The subjects may have particular pathological features such as liver fibrosis, a hepatic fat fraction (HFF) of at least about 10%, serum alanine aminotransferase (ALT) levels of at least about 30 U/L, and/or a NAFLD Activity Score (NAS) of at least 4 or 5.Type: ApplicationFiled: September 11, 2020Publication date: December 31, 2020Applicant: The General Hospital CorporationInventor: Steven K. GRINSPOON
-
Patent number: 10799562Abstract: The present application relates to novel methods for preventing, slowing the progression of, or treating nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), and/or liver fibrosis, and/or reducing the risks of liver cancer in subjects, such as HIV-infected subjects, using a GHRH molecule, e.g., trans-3-hexenoyl-GHRH(1-44)-NH2, or a pharmaceutically acceptable salt thereof. The subjects may have particular pathological features such as liver fibrosis, a hepatic fat fraction (HFF) of at least about 10%, serum alanine aminotransferase (ALT) levels of at least about 30 U/L, and/or a NAFLD Activity Score (NAS) of at least 4 or 5.Type: GrantFiled: March 27, 2020Date of Patent: October 13, 2020Assignee: THE GENERAL HOSPITAL CORPORATIONInventor: Steven K. Grinspoon
-
Publication number: 20200306345Abstract: The present application relates to novel methods for preventing, slowing the progression of, or treating nonalcoholic fatty liver (NAFL), nonalcoholic steatohepatitis (NASH), and/or liver fibrosis, and/or reducing the risks of liver cancer in subjects, such as HIV-infected subjects, using a GHRH molecule, e.g., trans-3-hexenoyl-GHRH(1-44)—NH2, or a pharmaceutically acceptable salt thereof. The subjects may have particular pathological features such as liver fibrosis, a hepatic fat fraction (HFF) of at least about 10%, serum alanine aminotransferase (ALT) levels of at least about 30 U/L, and/or a NAFLD Activity Score (NAS) of at least 4 or 5.Type: ApplicationFiled: March 27, 2020Publication date: October 1, 2020Applicant: THE GENERAL HOSPITAL CORPORATIONInventor: Steven K. GRINSPOON
-
Publication number: 20130244965Abstract: The invention is generally related to assays and methods for determining the risk of an HIV+ individual for developing a macrophage-mediated disease using measurement of soluble CD163 levels in a biological sample. The invention also provides assays and methods for monitoring efficacy of a treatment or a drug for a macrophage-mediated disease, and assays and methods for screening for agents to treat a macrophage-mediated disease in an HIV+ individual by monitoring soluble CD163 levels.Type: ApplicationFiled: September 27, 2011Publication date: September 19, 2013Applicants: THE GENERAL HOSPITAL CORPORATION, TRUSTEES OF BOSTON COLLEGEInventors: Kenneth C. Williams, Tricia Burdo, Steven K. Grinspoon, Eric Rosenberg
-
Publication number: 20120290327Abstract: A system and method provide nutrition assessments and tools for enabling users to achieve health-related goals based on specific health needs. The tools can include a nutrition assessment tool, a weight solution tool, a meal planning tool, and a meal tracking tool. The method includes receiving patient phenotype data. The phenotype data can include, but is not limited to, biometric data specific to the patient, medical claims data specific to the patient, organizational data specific to an organization to which the patient belongs, and behavioral data including dietary habits and nutritional history. One or more algorithms are executed on at least one processor of a computing apparatus to provide analyses of patient data in order. The results are output to a user in various web pages customized to provide features to the user.Type: ApplicationFiled: July 20, 2012Publication date: November 15, 2012Applicant: Phenotypeit, Inc.Inventors: Alaina B. Hanlon, Peter Connolly, Steven K. Grinspoon
-
Publication number: 20120072233Abstract: A system and method provide nutrition assessments and tools for enabling users to achieve health-related goals based on specific health needs. The tools can include a nutrition assessment tool, a weight solution tool, a meal planning tool, and a meal tracking tool. The method includes receiving patient phenotype data. The phenotype data can include, but is not limited to, biometric data specific to the patient, medical claims data specific to the patient, organizational data specific to an organization to which the patient belongs, and behavioral data including dietary habits and nutritional history. One or more algorithms are executed on at least one processor of a computing apparatus to provide analyses of patient data in order. The results are output to a user in various web pages customized to provide features to the user.Type: ApplicationFiled: September 20, 2011Publication date: March 22, 2012Inventors: Alaina B. Hanlon, Peter Connolly, Steven K. Grinspoon
-
Publication number: 20100249531Abstract: A system and method determine and report a potential for development by a patient of disease and adverse health conditions. The method includes receiving patient phenotype data. The phenotype data can include, but is not limited to, biometric data specific to the patient, medical claims data specific to the patient, and organizational data specific to an organization to which the patient belongs. One or more predictive models are generated using one or more algorithms executing on at least one processor of a computing apparatus. The one or more predictive models determine and indicate the potential for development by the patient of disease and adverse health conditions, and output the potential to a user.Type: ApplicationFiled: June 21, 2010Publication date: September 30, 2010Inventors: Alaina B. Hanlon, Peter Connolly, Steven K. Grinspoon